Vaccine
-
Randomized Controlled Trial Multicenter Study
Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
Individuals 50-64 years of age have reduced immune responses to influenza vaccines. The current study examined whether a high-dose inactivated trivalent influenza vaccine (IIV3-HD) might improve immune responses over a standard-dose inactivated influenza vaccine (IIV3-SD) in this age group. ⋯ The study suggests that in adults 50-64 years of age, IIV3-HD may improve immunogenicity compared to IIV3-SD while maintaining an acceptable safety profile.